Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Inotek's lead program, INO-8875, is a highly selective Adenosine-1 receptor agonist being evaluated for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The candidate has completed a Phase 1/2 clinical trial in patients and is currently being evaluated in a multiple-dose Phase 2 trial. In the Phase 1/2 study, treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP).

The Company has also been at the forefront of poly (ADP ribose) polymerase (PARP) inhibitor research and has a portfolio of superoxide dismutase (SOD) mimetics. Both PARP and SOD are attractive new targets in the field of retinal disease, and Inotek believes its PARP inhibitors and SOD mimetic compounds may hold significant potential in age-related macular degeneration and other ophthalmic indications.

Inotek has built a first-class drug development and management team to move the Company's programs forward in clinical trials. The Company is privately held and is based in Lexington, MA.